Skip to main navigation Skip to search Skip to main content

The study of antiarrhythmic medications in infancy (SAMIS): A multicenter, randomized controlled trial comparing the efficacy and safety of digoxin versus propranolol for prophylaxis of supraventricular tachycardia in infants

  • Shubhayan Sanatani
  • , James E. Potts
  • , John H. Reed
  • , J. Philip Saul
  • , Elizabeth A. Stephenson
  • , Karen A. Gibbs
  • , Charles C. Anderson
  • , Andrew S. MacKie
  • , Pamela S. Ro
  • , Svjetlana Tisma-Dupanovic
  • , Ronald J. Kanter
  • , Anjan S. Batra
  • , Anne Fournier
  • , Andrew D. Blaufox
  • , Harinder R. Singh
  • , Bertrand A. Ross
  • , Kenny K. Wong
  • , Yaniv Bar-Cohen
  • , Brian W. McCrindle
  • , Susan P. Etheridge
  • University of British Columbia
  • Medical University of South Carolina
  • University of Toronto
  • Sacred Heart Children's Hospital
  • Stollery Children's Hospital
  • University of Alberta
  • Nationwide Children’s Hospital
  • Ohio State University
  • Division of Cardiology
  • Children's Mercy Hospitals and Clinics
  • Duke University
  • University of California at Irvine
  • University of Montreal
  • Schneider Children's Hospital
  • Children's Hospital of Michigan
  • Wayne State University
  • Eastern Virginia Medical School
  • IWK Health Centre
  • Dalhousie University
  • Children's Hospital Los Angeles
  • University of Southern California
  • Primary Children's Medical Center
  • University of Utah

Research output: Contribution to journal › Article › peer-review

91 Scopus citations

Abstract

Background - Supraventricular tachycardia (SVT) is one of the most common conditions requiring emergent cardiac care in children, yet its management has never been subjected to a randomized controlled clinical trial. The purpose of this study was to compare the efficacy and safety of the 2 most commonly used medications for antiarrhythmic prophylaxis of SVT in infants: digoxin and propranolol. Methods and Results - This was a randomized, double-blind, multicenter study of infants <4 months with SVT (atrioventricular reciprocating tachycardia or atrioventricular nodal reentrant tachycardia), excluding Wolff-Parkinson-White, comparing digoxin with propranolol. The primary end point was recurrence of SVT requiring medical intervention. Time to recurrence and adverse events were secondary outcomes. Sixty-one patients completed the study, 27 randomized to digoxin and 34 to propranolol. SVT recurred in 19% of patients on digoxin and 31% of patients on propranolol (P=0.25). No first recurrence occurred after 110 days of treatment. The 6-month recurrence-free status was 79% for patients on digoxin and 67% for patients on propranolol (P=0.34), and there were no first recurrences in either group between 6 and 12 months. There were no deaths and no serious adverse events related to study medication. Conclusions - There was no difference in SVT recurrence in infants treated with digoxin versus propranolol. The current standard practice may be treating infants longer than required and indicates the need for a placebo-controlled trial.

Original languageEnglish
Pages (from-to)984-991
Number of pages8
JournalCirculation: Arrhythmia and Electrophysiology
Volume5
Issue number5
DOIs
StatePublished - Oct 2012
Externally publishedYes

Keywords

  • Clinical trials
  • Drugs
  • Patients
  • Pediatrics
  • Supraventricular tachycardia

Fingerprint

Dive into the research topics of 'The study of antiarrhythmic medications in infancy (SAMIS): A multicenter, randomized controlled trial comparing the efficacy and safety of digoxin versus propranolol for prophylaxis of supraventricular tachycardia in infants'. Together they form a unique fingerprint.

Cite this